Solomon Moshkevich Sells 875 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Key Points

• Insider Solomon Moshkevich sold 875 shares of Natera, Inc. at an average price of $155.46, amounting to a total of $136,027.50, reducing his ownership by 0.70%.
• Natera's stock reached $163.02, with a market capitalization of $22.37 billion, and the company reported a 32.2% increase in quarterly revenue year-over-year.
• Analyst ratings for Natera include multiple upgrades, with targets set as high as $220.00, while the overall consensus remains a “Moderate Buy.”

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 875 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total transaction of $136,027.50. Following the transaction, the insider owned 123,859 shares in the company, valued at approximately $19,255,120.14. The trade was a 0.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Friday, August 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $132.89, for a total value of $398,670.00.
• On Monday, July 28th, Solomon Moshkevich sold 2,206 shares of Natera stock. The stock was sold at an average price of $139.81, for a total value of $308,420.86.
• On Monday, July 21st, Solomon Moshkevich sold 291 shares of Natera stock. The stock was sold at an average price of $139.29, for a total transaction of $40,533.39.
• On Tuesday, May 27th, Solomon Moshkevich sold 1,649 shares of Natera stock. The shares were sold at an average price of $156.85, for a total transaction of $258,645.65.
• On Tuesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $166.77, for a total value of $500,310.00.
• On Monday, June 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $157.07, for a total value of $471,210.00.

Natera Stock Performance

Shares of NASDAQ NTRA traded up $4.58 during midday trading on Friday, hitting $163.02. 1,502,326 shares of the company's stock traded hands, compared to its average volume of 1,693,905. Natera, Inc. has a 1 year low of $110.57 and a 1 year high of $183.00. The firm has a fifty day moving average of $155.18 and a 200 day moving average of $154.75. The stock has a market capitalization of $22.37 billion, a price-to-earnings ratio of -85.35 and a beta of 1.76.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%. The business's quarterly revenue was up 32.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.30) earnings per share. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NTRA. Piper Sandler reissued an "overweight" rating and set a $220.00 price target (up from $210.00) on shares of Natera in a report on Monday. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 price target for the company in a research note on Monday, July 28th. Barclays reiterated an "overweight" rating and set a $210.00 price target (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Finally, Stephens restated an "overweight" rating and set a $183.00 price target on shares of Natera in a report on Friday. One research analyst has rated the stock with a sell rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $193.19.

Hedge Funds Weigh In On Natera

Several institutional investors have recently made changes to their positions in the company. LRI Investments LLC purchased a new stake in shares of Natera during the 4th quarter worth $29,000. Bank of Jackson Hole Trust acquired a new position in shares of Natera in the 1st quarter valued at $29,000. Hilltop National Bank purchased a new position in shares of Natera in the second quarter worth about $33,000. Oliver Lagore Vanvalin Investment Group purchased a new stake in Natera in the second quarter valued at $36,000. Finally, Rakuten Securities Inc. lifted its holdings in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after acquiring an additional 119 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.